Shareholders’ equity (deficiency) (Tables)

12 Months Ended

Dec. 31, 2024

Equity [Abstract]

Schedule of Stock Option Activity

A summary of the Company’s option activity and related information is as follows:

	Number of options	Weighted- average exercise price		Weighted- average remaining contractual term (in years)
Outstanding at December 31, 2023	15,728,176	$	3.83	6.23
Granted	913,672	10.93
Exercised	5,962,264	2.91
Forfeited	207,551	5.79
Outstanding at December 31, 2024	10,472,033	$	4.93	6.23
Exercisable at December 31, 2024	7,788,121	$	3.87	5.34

Schedule of Nonvested Restricted Stock Units Activity

A summary of the Company’s RSUs and PSUs activity is as follows:

	Number of RSUs	Weighted - average fair value
Unvested at December 31, 2023	8,160,149	$	5.97
Granted	3,289,358	10.63
Vested	3,327,010	5.95
Forfeited	832,526	6.81
Unvested, at December 31, 2024	7,289,971	$	7.99

Summary of Stock-Based Compensation

Share based compensation expenses related to the consolidated statements of operations recognized were comprised as follows:

	Year Ended December 31,
	2024		2023		2022
Cost of revenues	$	2,227	$	1,733	$	1,283
Research and development	6,663		4,673		2,974
Sales and marketing	10,216		6,478		5,041
General and administrative	11,469		6,114		4,410
	$	30,575	$	18,998	$	13,708